1Arner P.Insulin resistance in type 2 diabetes-role of the adipokines[J].Curr Mol Med,2005,5:333.
2Behre CJ,Brohall G,Hulthe L,et al..Serum saiponectin in a population sample of 61-year old women in relation to glucose toleranxe,family history of diabetes,autoimmunity,insulin sensitivity,C-peptide,and inflammation[J].Meabolism,2006,55:188.
4Laakso M,Suhonen M,Julkunen R,et al..Plasma inauhn serum lipids and lipoproteins in gall stonc diseasc in non-insulin dependent diabetic subjects:a case control study[J].Gut,1990,31:344.
5Wang Y,Xu A,Knight C,et al..Hydroxylatton and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin:potential role in the modulation of the insulin-sensitizing activity[J].Biol Chem,2002,277(22):10521.
6Yu JG,Javorschi S.The effect of thiazolidinediones on plaponectin levels in normal,oobese and type 2 diabetic subjects[J].Diabetes,2002,51(10):2968.
7Yokato T,Oritani K,Takahashi I,et al..Adiponectin,a new member of the family of soluble defense collagens,negatively regulates the growth of myelomonocytic progenitors and the functions of mecrophages[J].Blood,2000,96(15):1725.
8Matsuzawa Y,Funahashi T,Nakamura T,et al..Molexular mechanism of metabolic syndrome X:contribution of adipocytokines adipocytederived bioactive substances[J].European Joumal of Fndocrinology,2003,148:657.
9Agarwal AK,Miglani S,Singla S.Ultrasonographic evaluation of gallbladder volume in diabetics[J].J Aseoc Physicians India,2004,52:962.
10Fraquelli M,Pagliarulo M,Colucci A,et al..Gallbladder motility in obesity,diabetes mellitus and celiac disease[J].Dig Liver Dis,2003,35 (Suppl 3):S 12.
3Kondo H, Shimornura L, Matsukawa Y, et al. Associetion of adiponectinmutation with type 2 dibaetes : A candidate gene for the insulin resistance syndrome. Dibaetes ,2002,51:2325-2328.
4Barbora V, Norbort S, Robert S, et al. Low plasma adiponectin concentra- tions do not predict weight gain in humans. Diabetes, 2002,51:2964- 2967.
5Berg A_H, Combs TP, Du X, et al. The adipocyte secreted protein acrp30 enhances hepatic insulin action. Nat Med ,2001,7:947-953.
6Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk fac- tors, and cardiovascular events among patients, with end-stage renal dis- ease. J Am Soe Nephrol,2002,13 : 134-141.
7Laaksu M, Suhonen M, Julkunen R, et al. Plasma inauhn serum lipids and lipoproteins in gall stone disease in non-insulin dependent diabetic sub- jects : a case control study. Gut, 1990,31 : 344-348.
8Wang Y, Xu A, Knight C, et al. Hydroxylatton and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin: potential role in the modulation of the insulin-sensitizing activity. Biol Chem ,2002,277 : 10521-10527.
9Yu JG,Javorschi S. The effect of thiazolidinediones on plaponectin levels in normal,oobese and type2 diabetic subjects. Diabetes,2002,51:2968- 2972.
10Matsuzawa Y, Funahashi T, Nakamura T, et al. Molexular mechanism of metabolic syndrome X: contribution of adipocytokines adipocytederived bioactive substances. European Joumal of Fndocrinology, 2003, 148: 657-660.
